ClinicalTrials.gg
TerminatedNCT03437200CRUCIALUpdated Feb 21, 2023

Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer

A Phase 2 interventional study of Nivolumab and Ipilimumab in Inoperable œsophageal Cancer, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Terminated at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-21.

Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Phase 2, Interventional, and Treatment

Why this study was terminated
Poor accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The main objective of the trial is to assess the feasibility and the safety of the addition of immunotherapy with PD-1 antibody nivolumab +/- CTLA-4 antibody ipilimumab to concomitant chemoradiation therapy (CRT) in inoperable patients with early or locally advanced oesophageal cancer and to select the more promising experimental arm among the two possible combinations in terms of activity (based on progression free survival (PFS) at 12 months according to RECIST 1.1) for further evaluation in a phase III trial.

The secondary objectives will aim to evaluate progression-free survival, failure-free survival and overall survival and pattern of progression (including incidence of distance metastasis).

02

Conditions studied

  • Inoperable œsophageal Cancer

Keywords

  • œsophageal cancer nivolumab ipilimumab
03

In context

Lead sponsor

European Organisation for Research and Treatment of Cancer - EORTC is the lead sponsor of 352 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven oesophageal squamous cell carcinoma or adenocarcinoma
  • Both early stage and locally advanced tumor patients (according to TNM staging version 8):
  • T1, N1-3, M0 after complete work-up
  • T2, N0-3, M0 after complete work-up
  • T3, N0-3, M0
  • Patient eligible for definitive chemoradiation and not considered for primary surgery after multidisciplinary meeting decision or patient refuses to undergo surgery
  • Subject must be previously untreated with systemic treatment given as primary therapy for advanced or disease
  • At least one by CT scan or MRI based on version 1.1 with radiographic tumor assessment performed within 28 days prior to randomization
  • Availability of adequate tissue in terms of quality and quantity for immunohistochemical staining for PDL-1
  • 0 or 1
  • Adequate organ function within 14 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Cancer of cervical oesophagus (15 to 19 cm from dental ridge)
  • Known Her2 positive adenocarcinoma
  • Weight loss > 15 % over the last 3 months without improvement after nutritional support
  • Patient with cardiac dysfunction e.g. symptomatic congestive heart failure, uncontrolled hypertension
  • Known history of positive test for (HIV) or known acquired immunodeficiency syndrome (AIDS), or .
  • Any prior treatment for advanced disease including treatment with an anti-Programmed Death receptor-1 (), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, anti-cytotoxic T lymphocyte associated antigen-4 (anti-CTLA-4) antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
  • within 30 days prior to the first dose of study therapy. Examples of live vaccines include, but are not limited to the following: measles, mumps, rubella, chicken pox, yellow fever, H1N1 flu, rabies, BCG, and typhoid vaccine
  • History of to study drugs or any (refer to SmPCs for ipilimumab, nivolumab, 5-FU and oxaliplatin)
  • Current participation or treatment with an agent or use of an investigational agent within 4 weeks of the first dose of study treatment
  • Serious comorbidity or less than one year
  • to chemoradiation therapy
  • Treatment history of radiotherapy
  • B/C and patients with history of acute or chronic pancreatitis
  • Patient with Type I diabetes mellitus, or skin disorders
  • Known severe systemic disease affecting the lungs or the bowel
  • Known contraindication to CT scans with IV contrast
  • Chronic use of agents and/or systemic or any use in the last 15 days prior to enrollment
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • Autoimmune paraneoplastic syndrome requiring immunosuppressive or dedicated treatment
  • History of any other hematologic or primary solid tumor , unless in remission for at least 5 years.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Arm A: Chemoradiation + Nivolumab

    All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX followed by 3 cycles of 2 weeks of FOLFOX without RT. Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.

    Drug: Nivolumab · Other: Chemoradiation

  • Experimental
    Arm B: Chemoradiation + Nivolumab + Ipilimumab

    Same as arm A + induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year

    Drug: Nivolumab · Drug: Ipilimumab · Other: Chemoradiation

Interventions

  • Induction phase: Nivolumab IV 240 mg on days 1, 15 and 29 followed by a maintenance phase (to start on day 43) of Nivolumab IV 240 mg q2 weekly for up to 1 year.

  • Induction phase: Ipilimumab IV 1 mg/kg on day 1 followed by a maintenance phase (to start on day 43) of Ipilimumab IV 1 mg/kg q6 weekly for up to 1 year.

  • OtherChemoradiation

    All patients will receive standard fractionation radiation therapy (RT) scheme: 50Gy in 25 fractions over 5 weeks (i.e. 2Gy per fraction), concurrently with 3 cycles of 2 weeks of FOLFOX (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, bolus fluorouracil 400 mg/m2, and infusional fluorouracil 1600 mg/m2 over 48 h), followed by 3 cycles of 2 weeks of FOLFOX without RT.

06

What researchers measure

Primary outcomes

  1. 12-Month Progression-free survival using RECIST 1.1

    The analysis of the 12-Month Progression-free survival rate (PFS-12) will be done when all patients achieved at least 15 months follow-up (12 months for the primary endpoint plus 100 days after the end of the protocol treatment).

    Time frame: 3.8 years from first patient in

Secondary outcomes

  1. Best overall response according to RECIST 1.1

    Time frame: 3.8 years from first patient in

  2. Pattern of first cause of progression (either local relapse/progression,either regional relapse/progression, either distant metastasis)

    Time frame: 3.8 years from first patient in

  3. Progression-free survival using RECIST 1.1

    Time frame: 3.8 years from first patient in

  4. Failure-free survival

    Time frame: 3.8 years from first patient in

  5. Overall survival

    Time frame: 3.8 years from first patient in

  6. Percentage of patients receiving the planned chemoradiation

    Time frame: 3.8 years from first patient in

  7. Relative dose intensity of oxaliplatinum

    The dose intensity and relative dose intensity of treatments will be presented by drug and by treatment arm using median, range and interquartile range.

    Time frame: 3.8 years from first patient in

  8. Relative dose intensity of 5FU

    The dose intensity and relative dose intensity of treatments will be presented by drug and by treatment arm using median, range and interquartile range.

    Time frame: 3.8 years from first patient in

07

Study locations

7 sites
  • Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
    Paris, 75651, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Hospital Del Mar
    Barcelona, 08003, Spain
  • Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro
    Barcelona, 08304, Spain
  • Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
    Barcelona, 08908, Spain
  • Hospital Universitario de Gran Canaria Doctor Negrin
    Las Palmas De Gran Canaria, 35019, Spain
  • Hospital Universitario 12 De Octubre
    Madrid, 28041, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Oct 2022, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2018
First posted
Feb 19, 2018
StartActual
Jan 17, 2019
Primary completionActual
Oct 7, 2022
CompletionActual
Oct 7, 2022
Last update
Feb 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03437200
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Jan 17, 2019
Primary completion
Oct 7, 2022
Completion
Oct 7, 2022
Last update
Feb 21, 2023

Study contacts

Eric Deutsch
principal investigator · INSTITUT GUSTAVE ROUSSY, Paris, France
Markus Moehler
principal investigator · UNIVERSITY MEDICAL CENTER MAINZ, Germany

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion